Protocol Ledger

NCT04226248 · Phase III · COMPLETED

CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

Interventional Phase III clinical trial protocol NCT04226248 sponsored by University of Bristol in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-02 Enrollment: 600 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04226248
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)600 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04226248
Protocol FieldVerified Registry Value
NCT IdentifierNCT04226248
Consolidated Lead SponsorUniversity of Bristol
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment600 participants (ACTUAL)
Registered Start Date2020-01-02
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI